Management of COPD Exacerbations in Patients on Triple Therapy

Patient Selection and Assessment

The American Thoracic Society recommends that patients with COPD who are inadequately controlled on ICS/LABA plus LAMA should be considered for add-on therapy, such as macrolide maintenance therapy, if they continue to experience exacerbations despite triple therapy 1, 2
High-risk definition for COPD patients includes ≥2 moderate exacerbations OR ≥1 severe exacerbation (requiring hospitalization/ED visit) in the past year, with symptom burden assessed by CAT score ≥10 or mMRC ≥2, and lung function FEV₁ <80% predicted 1, 3, 4

The American College of Chest Physicians recommends adding azithromycin maintenance therapy for patients who continue to exacerbate despite triple therapy, with dosing options of 250 mg daily or 500 mg three times weekly 1, 2, 5
Azithromycin has moderate certainty of exacerbation reduction when added to LAMA/LABA/ICS, with benefits demonstrated over 1 year 1, 2, 5
Critical safety monitoring is required, including baseline and periodic hearing tests, ECG screening for QT prolongation and drug interactions, and monitoring for bacterial resistance development 1, 2, 5

Roflumilast may be considered as a second-line add-on therapy for patients with chronic bronchitic phenotype, with dosing starting at 250 mcg daily for 4 weeks, then increasing to 500 mcg daily 1, 2, 5, 6
The Global Initiative for Chronic Obstructive Lung Disease recommends that roflumilast should only be used in patients with severe-to-very severe COPD and a history of exacerbations 5, 6

Triple therapy (LAMA/LABA/ICS) has demonstrated mortality reduction compared to LAMA/LABA dual therapy in high-risk patients, with moderate certainty evidence for mortality benefit 4

Long-term oral corticosteroids have no role in chronic COPD management due to lack of benefit and high complication rates, and should be avoided 5
The American Thoracic Society recommends that patients on triple therapy should be monitored for adherence, inhaler technique, and potential adverse effects of add-on therapies 7